These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 37283493)
21. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830 [TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630 [TBL] [Abstract][Full Text] [Related]
23. Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications. Weth FR; Peng L; Paterson E; Tan ST; Gray C Cells; 2022 Dec; 12(1):. PubMed ID: 36611949 [TBL] [Abstract][Full Text] [Related]
24. Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy? Loong HH; Wong AM; Chan DT; Cheung MS; Chow C; Ding X; Chan AK; Johnston PA; Lau JY; Poon WS; Wong N J Clin Neurosci; 2020 Aug; 78():400-402. PubMed ID: 32340843 [TBL] [Abstract][Full Text] [Related]
25. Glioblastoma Model Using Human Cerebral Organoids. Ogawa J; Pao GM; Shokhirev MN; Verma IM Cell Rep; 2018 Apr; 23(4):1220-1229. PubMed ID: 29694897 [TBL] [Abstract][Full Text] [Related]
26. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model. Daher A; de Groot J Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369 [TBL] [Abstract][Full Text] [Related]
27. Maintaining Human Glioblastoma Cellular Diversity Ex vivo using Three-Dimensional Organoid Culture. Sundar SJ; Shakya S; Recinos V; Hubert CG J Vis Exp; 2022 Aug; (186):. PubMed ID: 36094291 [TBL] [Abstract][Full Text] [Related]
28. The generation of glioma organoids and the comparison of two culture methods. Zhang Y; Shao Y; Li Y; Li X; Zhang X; E Q; Wang W; Jiang Z; Gan W; Huang Y Cancer Med; 2024 Feb; 13(4):e7081. PubMed ID: 38457217 [TBL] [Abstract][Full Text] [Related]
29. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515 [TBL] [Abstract][Full Text] [Related]
30. Patient-derived cancer organoids for drug screening: Basic technology and clinical application. Ren X; Chen W; Yang Q; Li X; Xu L J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719 [TBL] [Abstract][Full Text] [Related]
31. Glioblastoma microenvironment: The stromal interactions. Uyar R Pathol Res Pract; 2022 Apr; 232():153813. PubMed ID: 35228161 [TBL] [Abstract][Full Text] [Related]
32. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment. Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620 [TBL] [Abstract][Full Text] [Related]
33. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797 [TBL] [Abstract][Full Text] [Related]
34. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study. Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038 [TBL] [Abstract][Full Text] [Related]
35. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544 [TBL] [Abstract][Full Text] [Related]
36. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma. Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897 [TBL] [Abstract][Full Text] [Related]
38. Exploiting Microglial Functions for the Treatment of Glioblastoma. Dello Russo C; Lisi L; Tentori L; Navarra P; Graziani G; Combs CK Curr Cancer Drug Targets; 2017; 17(3):267-281. PubMed ID: 27528361 [TBL] [Abstract][Full Text] [Related]
39. Organoid models of glioblastoma: advances, applications and challenges. Zhang C; Jin M; Zhao J; Chen J; Jin W Am J Cancer Res; 2020; 10(8):2242-2257. PubMed ID: 32905502 [TBL] [Abstract][Full Text] [Related]